Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review
It is over 50 years since the discovery of microtubules, and they have become one of the most important drug targets for anti-cancer therapies. Microtubules are predominantly composed of the protein tubulin, which contains a number of different binding sites for small-molecule drugs. There is contin...
Main Authors: | Eavan C. McLoughlin, Niamh M. O’Boyle |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-01-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/13/1/8 |
Similar Items
-
Discovery of new quinolines as potent colchicine binding site inhibitors: design, synthesis, docking studies, and anti-proliferative evaluation
by: Mohamed Hagras, et al.
Published: (2021-01-01) -
Modeling the Colchicum autumnale Tubulin and a Comparison of Its Interaction with Colchicine to Human Tubulin
by: Ivana Spasevska, et al.
Published: (2017-08-01) -
Identification of novel microtubule inhibitors effective in fission yeast and human cells and their effects on breast cancer cell lines
by: Jun Morishita, et al.
Published: (2021-09-01) -
Colchicine Blocks Tubulin Heterodimer Recycling by Tubulin Cofactors TBCA, TBCB, and TBCE
by: Sofia Nolasco, et al.
Published: (2021-04-01) -
Beyond the Paclitaxel and Vinca Alkaloids: Next Generation of Plant-Derived Microtubule-Targeting Agents with Potential Anticancer Activity
by: Dangquan Zhang, et al.
Published: (2020-06-01)